The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Harvoni Is Here: The Once-a-Day, Single Hep C Pill

Back to News Homepage

Next

A Win for Liver Transplant Patients with Hepatitis C

Second All-Oral Hep C Treatment Available: Less Expensive

November 13, 2014

Print this page

Olysio has been approved, in combination with Sovaldi, for the treatment of Hepatitis C. It is approximately $30,000 less than Harvoni (both of which consist of 12 weeks of therapy).

J&J Wins U.S. Approval for Hepatitis C Combo With Gilead

By Anna Edney

Johnson & Johnson (JNJ) won U.S. approval for its hepatitis C drug Olysio to be used in combination with Gilead Sciences Inc. (GILD)’s Sovaldi, making it the second all-oral treatment available for the most common form of the virus.

The Food and Drug Administration cleared the once-daily treatment for patients with hepatitis C genotype 1, J&J said yesterday in a statement. The combination allows Olysio to be used without the standard therapies including interferon, an injection that sometimes has flu-like side effects.

Continue reading this entire article:
http://www.bloomberg.com/news/2014-11-05/j-j-wins-u-s-approval-for-hepatitis-c-combo-with-gilead.html

13 Comments
Share
Share

Previous

Harvoni Is Here: The Once-a-Day, Single Hep C Pill

Back to News Homepage

Next

A Win for Liver Transplant Patients with Hepatitis C

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.